First patients test new pill targeting leukemia
NCT ID NCT05918692
Summary
This is the first study in people testing a new oral drug called BMF-500 for adults with acute myeloid leukemia (AML), a type of blood cancer. The main goals are to find a safe dose and see how the body handles the drug. The study will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
Texas Oncology-PA USOR
Dallas, Texas, 75251, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Kentucky - Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
Virginia Cancer Specialists
Gainesville, Virginia, 20155, United States
-
Winship Cancer Institute, Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.